Last reviewed · How we verify
NCT04794322
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
trial testing Uterine lavage, or a wash of the womb in Ovarian Neoplasms in 250 participants. Currently enrolling.
31 August 2027
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 13 April 2020 |
| Primary completion | 31 August 2027 |
| Estimated completion | 31 August 2028 |
| Sites | 6 locations across United States |
Drugs / interventions tested
- Uterine lavage, or a wash of the womb
- Blood sample — full drug profile →
- Pap smear
Conditions studied
- Ovarian Neoplasms — all drugs for Ovarian Neoplasms →
- Ovarian Epithelial Carcinoma — all drugs for Ovarian Epithelial Carcinoma →
- Fallopian Tube Neoplasms — all drugs for Fallopian Tube Neoplasms →
- High Grade Ovarian Serous Adenocarcinoma — all drugs for High Grade Ovarian Serous Adenocarcinoma →
Sponsor
Massachusetts General Hospital
Who can join
30 and older, female only, with Ovarian Neoplasms or Ovarian Epithelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the blood. The samples of the wash and the blood will be taken before surgery. After surgery, doctors will determine whether the participant had ovarian cancer or a benign disease of the ovaries. The tests of the washings and the blood will be examined to see how much the participants with ovarian cancer can be separated from the participants with a benign ovarian disease by the tests. Small amounts from the washing and the blood samples will be sent to four sites for analysis. Statistical analyses of these data will compare tumor DNA found in the washing of the uterus with proteins in the blood to detect cases of ovarian cancer. The primary goal is to find tests that are mostly positive for cases of ovarian cancer and mostly negative for patients with benign disease. It is hoped that if the tests work for participants with symptoms of the disease that these tests will also work when testing women who have no symptoms. A new study would be needed to see if the tests worked in this situation. If the tests work, this could lead to increasing the number of cases detected in early stage disease and decreasing the number of cases detected in late stage disease. If this change in late stage is large, it will likely reduce deaths due to ovarian cancer.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Molecular Management of High-Grade Serous Ovarian Carcinoma.
Punzón-Jiménez P, Lago V, Domingo S, Simón C, et al · · 2022 · cited 28× · PMID 36430255 · DOI 10.3390/ijms232213777 -
Early Ovarian Cancer Detection in the Age of Fallopian Tube Precursors: A Systematic Review.
Greenwood A, Woodruff ER, Nguyen C, Piper C, et al · · 2024 · cited 4× · PMID 38176019 · DOI 10.1097/aog.0000000000005496
Verify or expand the search:
- PubMed search for NCT04794322
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Neoplasms
Currently open trials in the same condition.
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07280312 — Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions · NA · recruiting
- NCT07038369 — A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · Phase 1 · active not recruiting
- NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
- NCT06751329 — A Study of DM002 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04794322 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 16 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04794322.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing